- China: Low US Interest Rates Threaten Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- White House Plans to Freeze Spending to Cut Deficit
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
MOST SHARED
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Today's Market Action
- Israel Going Green
- China's Role as Lender Alters Dynamics for United States
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
Text Size 
Giving everyone who's admitted to a hospital a quick test for the so-called "Superbug" doesn't significantly cut the number of infections and isn't cost-effective.
That's the conclusion of the biggest study yet that's just been published in the Journal of the American Medical Association. The journal also says in an editorial that hospitals can control the potentially fatal staph infections by using basic sanitary measures rather than "expensive" tests.
Researchers looked at nearly 22-thousand patients at a Swiss hospital who either got screened for the bacterial infection commonly known as MRSA or who used standard infection controls like hand gel. And they report that the universal testing did not reduce the incidence of MRSA infections.
Cepheid [CPHD
Loading...
()
] and Becton Dickinson [BDX
Loading...
()
] make MRSA tests which can give results much faster than the one used in the study and a few other companies are working on next-generation screening systems.
Cepheid CEO John Bishop told CNBC, "To say that it's (the MRSA test) not effective is an overstatement." Mr. Bishop said that MRSA is much less prevalent in Switzerland than in the U.S., so he argues it is much more difficult to show a reduction in infection rates in Switzerland than it is here.
In an email, Becton says this is just one "data point" and that many other studies have shown that testing for MRSA saves lives and money.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
Data is a real-time snapshot *Data is delayed at least 15 minutes